We conclude that MG produces pain through a TRPA1-AC1 signaling pathway, and suggest that future studies of novel therapeutics targeting TRPA1 or AC1 may benefit from an intraplantar MG administration model that recapitulates multiple behavioral signs and molecular mechanisms of painful diabetic neuropathy that are downstream of elevated MG. This evidence concerns the gene ADCY1 and diabetic neuropathy.